Talimogene laherparepvec - Amgen
Alternative Names: AMG-678; IMLYGIC; JS1/34.5- /47-/GM-CSF; OncoVEX; OncoVEXGM-CSF; T-VECLatest Information Update: 05 Apr 2024
At a glance
- Originator BioVex
- Developer Amgen; BioVex; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Merck & Co; Merck Sharp & Dohme Corp.; Roche; UNC Lineberger Comprehensive Cancer Center; University of California; University of Iowa
- Class Antineoplastics; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Malignant melanoma
- Phase II Basal cell cancer; Breast cancer; Soft tissue sarcoma
- Phase I/II Liver cancer; Malignant pleural effusion; Triple negative breast cancer
- Phase I Solid tumours
- No development reported Colorectal cancer; Head and neck cancer; HER2 negative breast cancer; Pancreatic cancer
Most Recent Events
- 26 Feb 2024 Amgen completes the phase II MASTERKEY-115 trial in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late stage disease, Metastatic disease, Second-line therapy or greater) in US, Australia, Canada, France, Germany, Greece, Italy, Netherlands, Poland, Spain, United Kingdom (Intralesional) (NCT04068181)
- 02 Jun 2023 Efficacy and safety data from a phase II trial in Malignant melanoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 10 May 2023 Amgen along with Medical University Vienna completes a phase II Neo-BCC trial in Basal cell cancer (Late-stage disease, Neoadjuvant therapy) in Austria (Intralesional) (EudraCT2018-002165-19)